Background: In October 2001, a paying antiretroviral therapy service was introduced at a Central Hospital in Malawi using stavudine 40 mg/lamivudine 150 mg/nevirapine 200 mg (triomune). The objective of this study was to determine characteristics of patients seeking antiretroviral therapy, retention in care, clinical outcomes, and outlines for program improvement. Methods: Retrospectively, all patients seeking antiretroviral therapy initiation (October 2001 to October 2002; follow-up through April 2003) were evaluated for laboratory results, retention in care, toxicity, and mortality. Hazard ratios for factors associated with dropout were determined. Results: Of 757 patients seeking evaluation, 625 began treatment. Documented mortality rate was 61 of 757. Total dropout rate was 50%. Factors associated with dropout include CD4 count <50 cells/mm 3 and Kaposi's sarcoma. Twenty-seven of 625 patients discontinued therapy for toxicity. Conclusions: The paying antiretroviral therapy program showed an unacceptable dropout rate associated with advanced baseline disease. Severe toxicity rate was low. Areas for improved program performance include lower cost, wide and earlier access to antiretroviral therapy, and targeted retention strategies.
Malawi, among the poorest countries in the world, has been among those most affected by the AIDS pandemic. Estimates from 2002 reveal an adult years) infection prevalence rate of 15%, with an overall prevalence of 9%. 1 As with other countries in the region, the cost of antiretroviral therapy (ART) has been a barrier to treatment for those in need. Early programs in other African countries have demonstrated demand for ART, feasibility of delivery, and efficacy of prescribed regimens. [2] [3] [4] In October 2001, the Malawi Ministry of Health, recognizing the increasing demand, introduced as a first step an antiretroviral program for paying clients using triomune (stavudine, lamivudine, nevirapine; Cipla Ltd, Mumbai, India) as the only available agent. The cost of $30 per month excluded the vast majority of the infected population, as Malawi's per capita income is below $200 per year. 5 The program was restricted to 2 central hospitals in the country: Kamuzu Central Hospital (KCH) in Lilongwe and the Queen Elizabeth Central Hospital in Blantyre. Neither national treatment guidelines nor other standards of care and documentation for ART had been developed at this stage. Malawi since has embarked on an ambitious, rapid countrywide rollout program of free antiretroviral treatment, which is currently reaching around 20 000 patients at 34 facilities (Ministry of Health HIV Unit, personal communication, March 2005).
Few data exist in Africans using the generic formulation of the medications in settings without alternative regimens and in settings as impoverished as Malawi without or before the addition of external resources. 6, 7 We describe and evaluate the first year of real-life experience of triomune, that is, delivery of ART outside a study protocol in Lilongwe, Malawi. We performed this retrospective analysis of this early phase to inform the further development and expansion of the national program.
Methods

Study Site
Kamuzu Central Hospital is a tertiary referral center for the central region of Malawi. Despite its tertiary designation, critical health resource shortages plague the system such that only 18% of nursing posts and 16% of laboratory technician posts are filled. 8 An estimated 90 000 HIV-infected persons live in the Lilongwe district; 15% to 20% of these may meet criteria for ART.
From October 1, 2001 , until June 30, 2002 , the antiretroviral clinic was located in the outpatient department of the KCH and operated one day per week for all initial and follow-up visits. Beginning July 1, 2002, the clinic moved to the newly established Lighthouse Trust Clinic (the Lighthouse) on the KCH campus and operated Monday through Friday, with new patient visits one day per week and follow-up visits daily.
Eligibility and Recruitment
General operations of the clinic included a baseline medical history and physical examination, a positive HIV test result, and laboratory work including a complete blood count and CD4 count. Patients were instructed to return 1 week after their initial visit for review and were started on ART if they met criteria for therapy and if there were no contraindications to treatment. From July 2002, group counseling was introduced for all new patients. The starting regimen during this time was limited to triomune once daily for 14 days, with dose escalation at 2 weeks, as additional antiretroviral medications were not available. Criteria for treatment initiation included any World Health Organization stage 3 or 4 diagnosis or CD4 count fewer than 200 cells/mm 3 . Patients with CD4 counts between 200 and 350 cells/mm 3 were offered the option of starting treatment, but generally, deferral of treatment until the CD4 count had dropped was recommended. Patients receiving tuberculosis treatment containing rifampin (the initial 2 months of treatment) were not started on ART until they had completed this phase of treatment. After starting medications, patients were instructed to return monthly for clinical review and to receive a refill of their ART medications. CD4 counts were recommended every 6 months. No routine safety monitoring was performed. Monitoring of patients in the program included laboratory evaluations (liver function tests) for clinical symptoms, provided that laboratory reagents were available. The direct cost for participating in the program included the monthly cost of the antiretroviral treatment (2500 Malawian Kwacha or US $25-$35) and payment for CD4 counts (1500 Malawian Kwacha or US $15-$20). Patients were asked during initial assessment whether they were able to cover the cost for the next 3 months. However, no systematic approach for confirming their financial resources was conducted.
The charts of all patients (age, >18 years) seeking antiretroviral initiation at KCH between October 1, 2001 , until October 30, 2002 , were reviewed for basic demographics, baseline laboratory results and clinical conditions, and previous antiretroviral history using a standard extraction tool by 1 of 4 trained reviewers. Records of those attending the clinic were updated weekly to determine retention in care, tolerance to medications, adherence to clinic visits, and new opportunistic infections. Follow-up for the cohort is through April 30, 2003, so each patient has the potential for a minimum of 6 months of follow-up time.
Patients were considered to have started ART if at least 1-month's prescription of ART was written. The protocol for analysis was approved by the University of North Carolina Institutional Review Board and was exempted from formal review by the National Health Sciences Review Committee in Malawi.
Outcome Measures
Loss to follow-up, or dropout, was defined as 2 missed appointments or no clinic visit in 90 days. Death was considered confirmed if reported to the clinic by a clinician, family member, or community member. No active tracing of defaulters was performed.
CD4 counts were performed with FACSCount Apparatus (Becton Dickinson, Mountain View, Calif). Baseline CD4 counts were determined as the most recent count preceding antiretroviral initiation.
The primary toxicities evaluated were skin rash, hepatitis, and neuropathy. Skin rash was categorized according to whether medication was discontinued or maintained. Hepatitis was defined as either clinical jaundice or symptoms suggestive of hepatitis with elevation of liver function test results. Neuropathy was defined clinically by patient report of pain, burning sensation, or numbness of the feet and/or hands. For toxicity assessment, patients required at least 1 follow-up visit after medication was started (2 visits). Patients who failed to return after their first prescription were categorized as unknown for toxicity status.
Statistical Analyses
All statistical analyses were performed using Stata 8.2 (Stata Corp, College Station, Tex).
We performed a descriptive analysis including bivariate analysis, Pearson χ 2 , paired t tests, and Wilcoxon rank sum was used as appropriate, according to the distribution of the values. We used Cox proportional hazards modeling to evaluate the relationship between loss to follow-up and baseline CD4 count, the use of ART, and certain medical conditions.
We assessed the effect of ART on loss to follow-up using Kaplan-Meier plots and the log rank statistic. Using a Cox model, the Kaplan-Meier plots were adjusted according to baseline CD4 count.
Results
General Characteristics
Of the 757 patients who sought evaluation for ART from October 2001 to October 2002, 701 (93%) were medically eligible, and 625 (83%) initiated therapy with triomune ( Figure 1) .
The median age of the cohort was 38 years (range, 19-72 years). Of the patients, 51.5% were male. Characteristics of the population revealed advanced AIDS in the majority of the patients with a median CD4 count of 70 cells/mm 3 (interquartile range, 17-160 cells/mm 3 ) and 43% of patients with CD4 count of 50 cells/mm 3 or fewer (Table 1) . Weight loss (66%), tuberculosis (43%), and thrush (46%) were the most common clinical conditions in the cohort. Kaposi's sarcoma was found in 11% of the patients.
Of the 625 patients starting ART, 53 (9%) of the patients had received dual therapy before initiation of triomune. Among the 56 patients who initially deferred ART because of having high CD4 counts, 21 (38%) eventually started therapy during the follow-up period. The median duration of care of all the subjects evaluated in this cohort was 187 days (interquartile range, 28-335 days). The median duration of triomune therapy in the cohort was 201 days (interquartile range, 49-337 days).
Retention
Overall, retention in the program was poor. Using failure to attend clinic in 90 days as loss to follow-up, 50% (376 of 757) of all patients initially evaluated for ART were no longer in care at the end of the evaluation period ( Figure 1 ). Included in this overall loss to follow-up rate were 61 confirmed deaths, representing a documented mortality rate of 8%, and 8 subjects known to have transferred to another facility. No difference was found between patients retained under care versus those lost to follow-up with regard to age and sex. Among those initiating ART, the loss to follow-up rate was 42% compared with 87% for those who did not begin ART (P < .0001). In both groups, loss to follow-up rate was highest during the first 90-day period: 30% in patients who started ART and 77% in those who did not.
No deaths were observed among those with high CD4 counts who deferred therapy.
Using Cox proportional hazards modeling to define independent factors associated with loss to follow-up, factors significantly associated with increased rate of loss were CD4 count fewer than 10 cells/mm 3 (hazard ratio = 2.33; 95% confidence interval [CI], 1.61-3.40) and CD4 count between 11 and 50 cells/mm 3 (hazard ratio = 1.67; 95% CI, 1.14-2.460; Table 2 ). Risk of loss to follow-up decreased as the baseline CD4 count increased. Other factors associated with increased rates of loss included having Kaposi's sarcoma and CD4 count between 51and 100 cells/mm 3 . Loss to follow-up was markedly reduced if ART was initiated (hazard ratio = 0.22; 95% CI, 0.16-0.30). The retentionin-care estimate curves according to the use of ART and adjusting for baseline CD4 count are depicted in Figure 2 .
Paying Antiretroviral Therapy Service in Malawi
Two years later, when free ART was introduced in Malawi's program (June 2004) and an electronic patient registration and follow-up system was started, 268 of the initially assessed 757 patients were reregistered at the Lighthouse. Among those were 63 (20.5%) who had previously been lost to follow-up.
Toxicity
Data for analysis of toxicity were available for 553 of 625 (88.5%) of the patients prescribed ART. Seventytwo (11.5%) patients failed to return for any follow-up visit, and toxicity could not be determined.
Overall, 4.5% (25 of 553) of patients starting ART were discontinued from medications for toxicity. Of the 553 patients evaluable for toxicity, 7 (1.3%) experienced hepatitis documented by jaundice and elevated liver function test results. Seventy-nine patients (14%) reported some form of rash, with 14 (2.5%) of these patients experiencing severe rash requiring discontinuation of therapy. One death secondary to Stevens-Johnson syndrome occurred in this group. Pancreatitis was diagnosed in 2 patients, and lactic acidemia was suspected in 2 patients, leading to discontinuation of therapy. Neuropathy was by far the most common toxicity, with 181 patients (34%) experiencing some degree of neuropathic-type symptoms, though 28 of these patients had the neuropathy documented before initiation of triomune. The majority of reported neuropathy was mild. Patients with a history of tuberculosis had slightly higher rates of neuropathy (36% vs 32%, P = .379), but this finding did not achieve statistical significance.
Immunology Outcomes
Although 337 patients received at least 6 months of ART, only 86 patients (25%) had a follow-up CD4 count performed after 6 months or more of treatment mainly because of the cost of the test. The mean increase in this group was 115 cells/mm 3 (95% CI, 89.4-140.6) going from a mean baseline of 109.3 cells/mm 3 (95% CI, 81.4-137.1) to 224 cells/mm 3 (95% CI, 188-260) (P < .0001). Among patients who had any exposure to dual therapy (n = 29) before initiation of triomune, the CD4 increase was a 100-cell (95% CI, 65-134) increase compared with a 122-cell increase (95% CI, 87-157) in those being completely naïve at the point of triomune (n = 57) initiation (P = .41).
Discussion
Recent publications of ART in resource-poor settings emphasize the feasibility and efficacy of these interventions. 3, 4, 6 In this article, we describe the first-year experience of the Malawian national antiretroviral program with generic fixed dose combination therapy in Lilongwe, Malawi.
Despite the potential biases because of the retrospective nature of our analysis and the low rate of immunologic follow-up, our data show similar results for immunologic outcomes and toxicity in comparison with data from studies from similar settings. 3,4,6 Toxicity rates requiring discontinuation of therapy were only 4.5%. This finding is likely an underestimation secondary to the high loss to follow-up and failure to monitor safety laboratories routinely. In the 2NN study that evaluated nonnucleoside reverse transcriptase inhibitor strategies for treatment, 22% of the patients on the nevirapine twice-daily regimen switched therapy for toxicity or HIV events, though rates of clinically diagnosed hepatitis and rash were similar. 9 Likewise, in the INCAS study, elevations of liver function test results occurred in 27% of subjects receiving nevirapine, with 5% of subjects discontinuing medications because of this laboratory abnormality. 10 More recently, using generic fixed-dose combination therapy in Cameroon similar to our program, 4 18% of patients had grade 3 or grade 4 adverse drug reactions.
The rates of neuropathy seen in our cohort (34%) exceeded those described by other clinical trials using stavudine. 11 Several factors likely explain this finding. Although triomune is manufactured as a fixed combination tablet in 2 dosages, weight-appropriate medications for those weighing fewer than 60 kg were not routinely available during this time period. Also, the lack of alternative therapy or dose reductions often resulted in continued use of the stavudine therapy despite the onset of symptoms. Concomitant or previous isoniazid therapy was common among this cohort, given those with a history of tuberculosis as well as suspected HIV-associated neuropathy. Although patients were accepting mild symptoms of neuropathy for the benefit of treatment, the high rate of neuropathy raises concern about the continuing widespread use of stavudine in similar patient populations.
The most intriguing finding of this analysis is the early and high loss to follow-up rate. Only a part of this loss can be explained by the documented mortality (8%). However, given the advanced state of baseline disease of the cohort, we suspect a large proportion of mortality was unreported. Overall, the cohort had low baseline CD4 counts, and counts were even lower among those lost to follow-up. This finding is not surprising, as baseline CD4 count is a strong predictor of opportunistic infections and associated mortality. Likewise, Kaposi's sarcoma patients were found to have a higher rate of loss to follow-up and again this may be secondary to mortality. Subsequent work by our group has confirmed much higher rates of mortality when patients who are lost to follow-up are followed up in the community. 12 Apart from medical reasons, our data suggest that direct and indirect costs for treatment are a major contributing factor to poor retention. The actual prescription of medication in our survey can serve as an indicator for the ability to pay for a particular patient at this point in time. In turn, not getting a prescription or not coming back can be interpreted as a proxy for the inability to pay, if not pretreatment mortality. 13 Thus, the high dropout rate even before initiating ART and within the first 3 months points in the direction of financial constraints as one of the major causes for this observation, even though the initial program selected for the less poor. This finding is also supported by the contrasting results to another antiretroviral program in South Africa, where medications are provided free and enrollment is restricted to local residents. 14 This program's dropout rates were much lower, despite similarly advanced-status patients. Furthermore, considering interim death and opening of new treatment centers over time, a considerable 20.5% of those who were lost to follow-up returned to care when drugs became freely available in June 2004.
With a goal of maintaining patients in care and on effective ART, several observations and conclusions emerge from the experience of the cohort. 1 . The paying open ART program at KCH had an unacceptable high dropout rate, which could be explained partially through the collected data and may be secondary to the involved cost and higher than reported mortality rates. As programs scale up, a component of program implementation should include resources for follow-up and retention of clients such that mortality and toxicity events can be determined accurately. Targeted interventions of those at highest risk for loss to follow-up, that is, mortality (characterized by low CD4 counts or advanced clinical stage), may be useful to improve program performance. The Lighthouse since has included an adherence support component to its community home-based care program that addresses the need for regular followthrough visits of patients by volunteers. The effect of this component has not yet been evaluated. 2. The high cost of CD4 count testing was a barrier to obtaining consistent information regarding immunologic improvement of patients initiating ART. In highly impoverished countries, laboratory costs should be borne by the program rather than by the patient for evaluation of program performance. 3. Among patients who remain in care and take ART, clinical and immunologic benefit is possible. However, the high rates of dropout among those with the lowest CD4 counts suggest that although late presentation successes can occur, earlier initiation of therapy will likely improve outcomes. Wider access and the promotion of early health-careseeking behavior should be a component of HIV education programs associated with the HIV clinics. 4. The expansion of available agents for lead-in dosing, body weight, and toxicity substitution will likely improve program performance and prevent toxicity and emergence of resistance.
Paying Antiretroviral Therapy Service in Malawi 5 . Standardized procedures for the entire process from enrolling patients to record keeping are necessary to support quality of care in settings with high demand for clinical services. The Lighthouse has developed an initiation visit checklist and follow-up visit checklists to conform to reporting requirements for the Ministry of Health and to support clinical care. The Lighthouse has added an electronic patient management system to promote reporting.
Based on the paying program's performance and with funding from the Global Fund to Fight AIDS, Tuberculosis & Malaria, Malawi has elected to move to a free antiretroviral program with first-line therapy available nationally at more than 50 centers and expanded antiretroviral access at central hospitals. 15, 16 Given the promising data from documented ART interventions in high-burden, poor African countries and despite growing donor support and patients' willingness to pay, we emphasize the need for sustained longterm financing mechanisms both for the necessary health system infrastructure and for treatment free of charge at the point of delivery for those in need. 17 
